Use of antimalarials in dermatology
Identifieur interne : 000024 ( Istex/Corpus ); précédent : 000023; suivant : 000025Use of antimalarials in dermatology
Auteurs : Falk R. OchsendorfSource :
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft [ 1610-0379 ] ; 2010-10.
English descriptors
- Teeft :
- Abdominal cramps, Academy figure, Academy table, Accommodation disorders, Actual weight, Acute intoxication, Adipose tissue, Adverse effects, Amphiphilic molecules, Amsler grid test, Annual controls, Antigen presentation, Antimalarial, Antimalarial agents, Antimalarial drug therapy, Antimalarial drugs, Antimalarial therapy, Aplastic anemia, Arch dermatol, Author journal compilation blackwell verlag gmbh, Berlin jddg, Berlin jddg academy, Berlin jddg academy table, Berlin jddg jddg, Blackwell, Blood lipids, Body weight, British recommendations, Case reports, Case series, Chloroquine, Chloroquine diphosphate, Clin dermatol, Clinical controls, Clinical improvement, Color vision testing, Combination therapy, Conduction disorders, Control group, Corticosteroid, Cutaneous, Cutaneous lupus, Cutaneous sarcoidosis, Daily dosages, Daily dose, Deep compartments, Dermatol, Dermatomyositis, Dosage, Drug interactions, Erosive lichen planus, Erythematosus, Fewer side effects, G6pd activity, Gleichen teilen, Glucose tolerance, Gmbh, Greater detail, Heavier ones, Heavier patients, Hemolytic effects, Higher dosages, Hydroxychloroquine, Ideal body weight, Ideal weight, Individual basis, Inflammatory diseases, Jddg, Kidney dysfunction, Lichen, Lichen planus, Lighter patients, Liver function, Liver insufficiency, Liver values, Lupus, Lupus erythematosus, Lupus erythematosus tumidus, Lupus flares, Lupus panniculitis, Malaria prophylaxis, Maximum dosage, Maximum effectiveness, Maximum plasma levels, More detail, Necrobiosis lipoidica, Older patients, Ophthalmological examinations, Other diseases, Patient series, Phospholipid antibodies, Planus, Plasma levels, Plasma proteins, Polymorphous light eruption, Poorer response, Porphyria, Porphyria cutanea tarda, Porphyrin excretion, Positive effect, Pregnant women, Protective effect, Psoriasis, Quinacrine, Response rate, Retinopathy, Rheumatoid arthritis, Safe therapy, Sarcoidosis, Semin arthritis rheum, Side effects, Significant reduction, Single dose, Skin diseases, Skin lesions, Skin reactions, Small children, Small number, Standard therapies, Steroid therapy, Syndrome, Synergistic effect, Systematic review, Systemic, Systemic lupus, Systemic lupus erythematosus, Tablet, Tagesdosis liegen, Therapeutic dosages, Therapy, Thrombocyte aggregation, Verlag, Vision field testing, Weight range, Welchem bereich sollte.
Abstract
The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.
Url:
DOI: 10.1111/j.1610-0387.2010.07490.x
Links to Exploration step
ISTEX:1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of antimalarials in dermatology</title><author><name sortKey="Ochsendorf, Falk R" sort="Ochsendorf, Falk R" uniqKey="Ochsendorf F" first="Falk R." last="Ochsendorf">Falk R. Ochsendorf</name><affiliation><mods:affiliation>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1610-0387.2010.07490.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000024</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000024</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Use of antimalarials in dermatology</title><author><name sortKey="Ochsendorf, Falk R" sort="Ochsendorf, Falk R" uniqKey="Ochsendorf F" first="Falk R." last="Ochsendorf">Falk R. Ochsendorf</name><affiliation><mods:affiliation>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><title level="j" type="alt">JDDG JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT</title><idno type="ISSN">1610-0379</idno><idno type="eISSN">1610-0387</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="829">829</biblScope><biblScope unit="page" to="845">845</biblScope><biblScope unit="page-count">17</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-10">2010-10</date></imprint><idno type="ISSN">1610-0379</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1610-0379</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abdominal cramps</term><term>Academy figure</term><term>Academy table</term><term>Accommodation disorders</term><term>Actual weight</term><term>Acute intoxication</term><term>Adipose tissue</term><term>Adverse effects</term><term>Amphiphilic molecules</term><term>Amsler grid test</term><term>Annual controls</term><term>Antigen presentation</term><term>Antimalarial</term><term>Antimalarial agents</term><term>Antimalarial drug therapy</term><term>Antimalarial drugs</term><term>Antimalarial therapy</term><term>Aplastic anemia</term><term>Arch dermatol</term><term>Author journal compilation blackwell verlag gmbh</term><term>Berlin jddg</term><term>Berlin jddg academy</term><term>Berlin jddg academy table</term><term>Berlin jddg jddg</term><term>Blackwell</term><term>Blood lipids</term><term>Body weight</term><term>British recommendations</term><term>Case reports</term><term>Case series</term><term>Chloroquine</term><term>Chloroquine diphosphate</term><term>Clin dermatol</term><term>Clinical controls</term><term>Clinical improvement</term><term>Color vision testing</term><term>Combination therapy</term><term>Conduction disorders</term><term>Control group</term><term>Corticosteroid</term><term>Cutaneous</term><term>Cutaneous lupus</term><term>Cutaneous sarcoidosis</term><term>Daily dosages</term><term>Daily dose</term><term>Deep compartments</term><term>Dermatol</term><term>Dermatomyositis</term><term>Dosage</term><term>Drug interactions</term><term>Erosive lichen planus</term><term>Erythematosus</term><term>Fewer side effects</term><term>G6pd activity</term><term>Gleichen teilen</term><term>Glucose tolerance</term><term>Gmbh</term><term>Greater detail</term><term>Heavier ones</term><term>Heavier patients</term><term>Hemolytic effects</term><term>Higher dosages</term><term>Hydroxychloroquine</term><term>Ideal body weight</term><term>Ideal weight</term><term>Individual basis</term><term>Inflammatory diseases</term><term>Jddg</term><term>Kidney dysfunction</term><term>Lichen</term><term>Lichen planus</term><term>Lighter patients</term><term>Liver function</term><term>Liver insufficiency</term><term>Liver values</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus tumidus</term><term>Lupus flares</term><term>Lupus panniculitis</term><term>Malaria prophylaxis</term><term>Maximum dosage</term><term>Maximum effectiveness</term><term>Maximum plasma levels</term><term>More detail</term><term>Necrobiosis lipoidica</term><term>Older patients</term><term>Ophthalmological examinations</term><term>Other diseases</term><term>Patient series</term><term>Phospholipid antibodies</term><term>Planus</term><term>Plasma levels</term><term>Plasma proteins</term><term>Polymorphous light eruption</term><term>Poorer response</term><term>Porphyria</term><term>Porphyria cutanea tarda</term><term>Porphyrin excretion</term><term>Positive effect</term><term>Pregnant women</term><term>Protective effect</term><term>Psoriasis</term><term>Quinacrine</term><term>Response rate</term><term>Retinopathy</term><term>Rheumatoid arthritis</term><term>Safe therapy</term><term>Sarcoidosis</term><term>Semin arthritis rheum</term><term>Side effects</term><term>Significant reduction</term><term>Single dose</term><term>Skin diseases</term><term>Skin lesions</term><term>Skin reactions</term><term>Small children</term><term>Small number</term><term>Standard therapies</term><term>Steroid therapy</term><term>Syndrome</term><term>Synergistic effect</term><term>Systematic review</term><term>Systemic</term><term>Systemic lupus</term><term>Systemic lupus erythematosus</term><term>Tablet</term><term>Tagesdosis liegen</term><term>Therapeutic dosages</term><term>Therapy</term><term>Thrombocyte aggregation</term><term>Verlag</term><term>Vision field testing</term><term>Weight range</term><term>Welchem bereich sollte</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>antimalarial</json:string><json:string>lupus</json:string><json:string>chloroquine</json:string><json:string>jddg</json:string><json:string>quinacrine</json:string><json:string>hydroxychloroquine</json:string><json:string>erythematosus</json:string><json:string>cutaneous</json:string><json:string>gmbh</json:string><json:string>antimalarial drugs</json:string><json:string>author journal compilation blackwell verlag gmbh</json:string><json:string>verlag</json:string><json:string>ideal body weight</json:string><json:string>side effects</json:string><json:string>lichen</json:string><json:string>planus</json:string><json:string>retinopathy</json:string><json:string>adverse effects</json:string><json:string>sarcoidosis</json:string><json:string>porphyria</json:string><json:string>case reports</json:string><json:string>dermatol</json:string><json:string>dermatomyositis</json:string><json:string>corticosteroid</json:string><json:string>dosage</json:string><json:string>psoriasis</json:string><json:string>combination therapy</json:string><json:string>response rate</json:string><json:string>actual weight</json:string><json:string>deep compartments</json:string><json:string>berlin jddg jddg</json:string><json:string>lichen planus</json:string><json:string>antimalarial therapy</json:string><json:string>rheumatoid arthritis</json:string><json:string>porphyria cutanea tarda</json:string><json:string>thrombocyte aggregation</json:string><json:string>adipose tissue</json:string><json:string>cutaneous lupus</json:string><json:string>pregnant women</json:string><json:string>arch dermatol</json:string><json:string>daily dosages</json:string><json:string>systemic lupus</json:string><json:string>lighter patients</json:string><json:string>antimalarial agents</json:string><json:string>case series</json:string><json:string>higher dosages</json:string><json:string>therapy</json:string><json:string>daily dose</json:string><json:string>berlin jddg academy</json:string><json:string>amsler grid test</json:string><json:string>ideal weight</json:string><json:string>individual basis</json:string><json:string>plasma levels</json:string><json:string>patient series</json:string><json:string>systemic lupus erythematosus</json:string><json:string>standard therapies</json:string><json:string>kidney dysfunction</json:string><json:string>lupus panniculitis</json:string><json:string>lupus erythematosus</json:string><json:string>lupus erythematosus tumidus</json:string><json:string>systematic review</json:string><json:string>blood lipids</json:string><json:string>body weight</json:string><json:string>polymorphous light eruption</json:string><json:string>syndrome</json:string><json:string>blackwell</json:string><json:string>heavier patients</json:string><json:string>tagesdosis liegen</json:string><json:string>academy table</json:string><json:string>weight range</json:string><json:string>heavier ones</json:string><json:string>glucose tolerance</json:string><json:string>liver function</json:string><json:string>abdominal cramps</json:string><json:string>accommodation disorders</json:string><json:string>porphyrin excretion</json:string><json:string>amphiphilic molecules</json:string><json:string>drug interactions</json:string><json:string>skin reactions</json:string><json:string>g6pd activity</json:string><json:string>antimalarial drug therapy</json:string><json:string>clinical controls</json:string><json:string>chloroquine diphosphate</json:string><json:string>small children</json:string><json:string>more detail</json:string><json:string>therapeutic dosages</json:string><json:string>vision field testing</json:string><json:string>color vision testing</json:string><json:string>greater detail</json:string><json:string>annual controls</json:string><json:string>liver insufficiency</json:string><json:string>berlin jddg academy table</json:string><json:string>british recommendations</json:string><json:string>ophthalmological examinations</json:string><json:string>small number</json:string><json:string>fewer side effects</json:string><json:string>conduction disorders</json:string><json:string>malaria prophylaxis</json:string><json:string>antigen presentation</json:string><json:string>hemolytic effects</json:string><json:string>inflammatory diseases</json:string><json:string>aplastic anemia</json:string><json:string>lupus flares</json:string><json:string>welchem bereich sollte</json:string><json:string>control group</json:string><json:string>liver values</json:string><json:string>gleichen teilen</json:string><json:string>maximum plasma levels</json:string><json:string>poorer response</json:string><json:string>maximum effectiveness</json:string><json:string>plasma proteins</json:string><json:string>cutaneous sarcoidosis</json:string><json:string>older patients</json:string><json:string>synergistic effect</json:string><json:string>single dose</json:string><json:string>positive effect</json:string><json:string>erosive lichen planus</json:string><json:string>protective effect</json:string><json:string>acute intoxication</json:string><json:string>academy figure</json:string><json:string>steroid therapy</json:string><json:string>skin lesions</json:string><json:string>significant reduction</json:string><json:string>maximum dosage</json:string><json:string>clinical improvement</json:string><json:string>skin diseases</json:string><json:string>necrobiosis lipoidica</json:string><json:string>phospholipid antibodies</json:string><json:string>safe therapy</json:string><json:string>clin dermatol</json:string><json:string>semin arthritis rheum</json:string><json:string>other diseases</json:string><json:string>berlin jddg</json:string><json:string>tablet</json:string><json:string>systemic</json:string></teeft></keywords><author><json:item><name>Falk R. Ochsendorf</name><affiliations><json:string>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>chloroquine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hydroxychloroquine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>quinacrine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lupus erythematosus</value></json:item></subject><articleId><json:string>DDG7490</json:string></articleId><arkIstex>ark:/67375/WNG-TF6GR5N0-G</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</abstract><qualityIndicators><score>9.4</score><pdfWordCount>7979</pdfWordCount><pdfCharCount>51506</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>17</pdfPageCount><pdfPageSize>595.276 x 841.89 pts (A4)</pdfPageSize><pdfWordsPerPage>469</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>200</abstractWordCount><abstractCharCount>1375</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Use of antimalarials in dermatology</title><pmid><json:string>20678149</json:string></pmid><genre><json:string>article</json:string></genre><host><title>JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1610-0387</json:string></doi><issn><json:string>1610-0379</json:string></issn><eissn><json:string>1610-0387</json:string></eissn><publisherId><json:string>DDG</json:string></publisherId><volume>8</volume><issue>10</issue><pages><first>829</first><last>845</last><total>17</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Academy/AkademieCME</value></json:item><json:item><value>CME</value></json:item></subject></host><namedEntities><unitex><date><json:string>1934</json:string><json:string>1950s</json:string><json:string>1930</json:string><json:string>1999</json:string><json:string>2010</json:string><json:string>1951</json:string></date><geogName></geogName><orgName><json:string>Universität Theodor-Stern-Kai</json:string><json:string>University of Frankfurt Hospital, Frankfurt</json:string><json:string>Germany Section Editor</json:string><json:string>American College of Rheumatology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Studies</json:string><json:string>J.W. Goethe</json:string><json:string>The</json:string><json:string>Wallace</json:string><json:string>Dr</json:string><json:string>Case</json:string></persName><placeName><json:string>Germany</json:string><json:string>Frankfurt</json:string><json:string>Ochsendorf</json:string></placeName><ref_url><json:string>http://www.pharmavertrieb-heinze.de/</json:string><json:string>http://www.bcm-specials.co.uk/</json:string></ref_url><ref_bibl><json:string>[14, 15]</json:string><json:string>[4]</json:string><json:string>[12]</json:string><json:string>[6]</json:string><json:string>[11]</json:string><json:string>[8]</json:string><json:string>[1]</json:string><json:string>[10]</json:string><json:string>[16]</json:string><json:string>[3]</json:string><json:string>[20]</json:string><json:string>[5, 6]</json:string><json:string>[7]</json:string><json:string>[14]</json:string><json:string>[9]</json:string><json:string>[2]</json:string><json:string>[13]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-TF6GR5N0-G</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - dermatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - dermatology & venereal diseases</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Dermatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1610-0387.2010.07490.x</json:string></doi><id>1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Use of antimalarials in dermatology</title><title level="a" type="short">Academy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© The Author • Journal compilation © Blackwell Verlag GmbH, Berlin</licence></availability><date type="published" when="2010-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Use of antimalarials in dermatology</title><title level="a" type="short">Academy</title><author xml:id="author-0000"><persName><forename type="first">Falk R.</forename><surname>Ochsendorf</surname></persName><affiliation><orgName type="department">Department of Dermatology</orgName><orgName type="institution">Venerology and Allergy University of Frankfurt Hospital</orgName><address><addrLine>Frankfurt am Main</addrLine><addrLine>Germany</addrLine><country key="DE" xml:lang="en">GERMANY</country></address></affiliation></author><idno type="istex">1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A</idno><idno type="ark">ark:/67375/WNG-TF6GR5N0-G</idno><idno type="DOI">10.1111/j.1610-0387.2010.07490.x</idno><idno type="unit">DDG7490</idno><idno type="toTypesetVersion">file:DDG.DDG7490.pdf</idno></analytic><monogr><title level="j" type="main">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><title level="j" type="alt">JDDG JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT</title><idno type="pISSN">1610-0379</idno><idno type="eISSN">1610-0387</idno><idno type="book-DOI">10.1111/(ISSN)1610-0387</idno><idno type="book-part-DOI">10.1111/ddg.2010.8.issue-10</idno><idno type="product">DDG</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="829">829</biblScope><biblScope unit="page" to="845">845</biblScope><biblScope unit="page-count">17</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Summary</head><p>The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram <hi rend="italic">ideal</hi> body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">chloroquine</term><term xml:id="k2">hydroxychloroquine</term><term xml:id="k3">quinacrine</term><term xml:id="k4">lupus erythematosus</term></keywords><keywords rend="tocHeading1"><term>Academy/Akademie
CME</term></keywords><keywords rend="articleCategory"><term>CME
</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1610-0387</doi><issn type="print">1610-0379</issn><issn type="electronic">1610-0387</issn><idGroup><id type="product" value="DDG"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JDDG JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title></titleGroup></publicationMeta><publicationMeta level="part" position="10110"><doi origin="wiley">10.1111/ddg.2010.8.issue-10</doi><numberingGroup><numbering type="journalVolume" number="8">8</numbering><numbering type="journalIssue" number="10">10</numbering></numberingGroup><coverDate startDate="2010-10">October 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="21" status="forIssue"><doi origin="wiley">10.1111/j.1610-0387.2010.07490.x</doi><idGroup><id type="unit" value="DDG7490"></id></idGroup><countGroup><count type="pageTotal" number="17"></count></countGroup><titleGroup><title type="tocHeading1">Academy/Akademie
CME</title><title type="articleCategory">CME
</title></titleGroup><copyright>© The Author • Journal compilation © Blackwell Verlag GmbH, Berlin</copyright><eventGroup><event type="firstOnline" date="2010-07-30"></event><event type="publishedOnlineFinalForm" date="2010-07-30"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.20 mode:FullText" date="2010-09-24"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-07-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-17"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="829">829</numbering><numbering type="pageLast" number="845">845</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:DDG.DDG7490.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Submitted: 14. 3. 2010 | Accepted: 1. 6. 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="6"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="21"></count><count type="linksCrossRef" number="62"></count></countGroup><titleGroup><title type="main">Use of antimalarials in dermatology</title><title type="shortAuthors">Academy</title><title type="short">Academy</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Falk R.</givenNames><familyName>Ochsendorf</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="DE"><unparsedAffiliation>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">chloroquine</keyword><keyword xml:id="k2">hydroxychloroquine</keyword><keyword xml:id="k3">quinacrine</keyword><keyword xml:id="k4">lupus erythematosus</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Summary</title><p>The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram <i>ideal</i> body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1"><p>Section Editor
Prof. Dr. Jan C. Simon,
Leipzig</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Use of antimalarials in dermatology</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Academy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Use of antimalarials in dermatology</title></titleInfo><name type="personal"><namePart type="given">Falk R.</namePart><namePart type="family">Ochsendorf</namePart><affiliation>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2010-10</dateIssued><edition>Submitted: 14. 3. 2010 | Accepted: 1. 6. 2010</edition><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">6</extent><extent unit="formulas">0</extent><extent unit="references">21</extent><extent unit="linksCrossRef">62</extent></physicalDescription><abstract lang="en">The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</abstract><subject lang="en"><genre>keywords</genre><topic>chloroquine</topic><topic>hydroxychloroquine</topic><topic>quinacrine</topic><topic>lupus erythematosus</topic></subject><relatedItem type="host"><titleInfo><title>JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Academy/AkademieCME</topic><topic>CME</topic></subject><identifier type="ISSN">1610-0379</identifier><identifier type="eISSN">1610-0387</identifier><identifier type="DOI">10.1111/(ISSN)1610-0387</identifier><identifier type="PublisherID">DDG</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>829</start><end>845</end><total>17</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Antimalarials: unapproved uses or indications</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Wolf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Wolf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Ruocco</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wolf R, Wolf D, Ruocco V. Antimalarials: unapproved uses or indications. Clin Dermatol 2000; 18: 17–35.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>17</start><end>35</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Dermatol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>17</start><end>35</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>New concepts in antimalarial use and mode of action in dermatology</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kalia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Dutz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20: 160–74.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>160</start><end>74</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>160</start><end>74</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Ducharme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Farinotti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996; 31: 257–74.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>257</start><end>74</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacokinet</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>257</start><end>74</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Wallace</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989; 18: 282–96.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>282</start><end>96</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>282</start><end>96</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Antimalarials in rheumatology: efficacy and safety</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Maksymowych</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Russell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206–21.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>206</start><end>21</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>206</start><end>21</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Chloroquin‐Retinopathie: durch individuelle Tagesdosis vermeidbar</title></titleInfo><name type="personal"><namePart type="given">FR</namePart><namePart type="family">Ochsendorf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Runne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Goerz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Zrenner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ochsendorf FR, Runne U, Goerz G, Zrenner E. Chloroquin‐Retinopathie: durch individuelle Tagesdosis vermeidbar. Dtsch med Wschr 1993; 118: 1895–8.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><extent unit="pages"><start>1895</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Dtsch med Wschr</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><extent unit="pages"><start>1895</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika</title></titleInfo><name type="personal"><namePart type="given">FR</namePart><namePart type="family">Ochsendorf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Runne</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ochsendorf FR, Runne U. Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika. Hautarzt 1991; 42: 140–6.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>140</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Hautarzt</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>140</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Kutaner Lupus erythematodes</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Bonsmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>other</genre><part><date>2008</date></part></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Survival after massive hydroxychloroquine overdose</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Gunja</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Roberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">McCoubrie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Lamberth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Jan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DC</namePart><namePart type="family">Simes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Hackett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NA</namePart><namePart type="family">Buckley</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, Hackett P, Buckley NA. Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care 2009; 37: 130–3.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>130</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Anaesth Intensive Care</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>130</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Screening for antimalarial toxicity: current concepts</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Easterbrook</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 2002; 37: 325–8, 331–4.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>325</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Can J Ophthalmol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>325</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Ocular toxicity and hydroxychloroquine: guidelines for screening</title></titleInfo><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 3–7.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>3</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>3</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>The role of antimalarials in the exacerbation of psoriasis: a systematic review</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Herman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Shin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Holbrook</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Rosenthal</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol 2006; 7: 249–57.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>249</start><end>57</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Clin Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>249</start><end>57</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Disease‐modifying antirheumatic drugs in pregnancy: current status and implications for the future</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Vroom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HE</namePart><namePart type="family">De Walle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Van De Laar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Brouwers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LT</namePart><namePart type="family">De Jong‐van den Berg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vroom F, De Walle HE, Van De Laar MA, Brouwers JR, De Jong‐van den Berg LT. Disease‐modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006; 29: 845–63.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>845</start><end>63</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>845</start><end>63</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kreuter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Gaifullina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Tigges</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kirschke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Altmeyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gambichler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145: 244–8.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>244</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><extent unit="pages"><start>244</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Lupus erythematosus tumidus. A neglected subset of cutaneous lupus erythematosus: report of 40 cases</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Richter‐Hintz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Oslislo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Megahed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Lehmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Richter‐Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P. Lupus erythematosus tumidus. A neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033–41.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>1033</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>136</number></detail><extent unit="pages"><start>1033</start><end>41</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Ruiz‐Irastorza</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ramos‐Casals</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Brito‐Zeron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Khamashta</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruiz‐Irastorza G, Ramos‐Casals M, Brito‐Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–8.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>20</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>20</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Wollina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kostler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Koch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Riedel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Stolzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wollina U, Kostler E, Koch A, Riedel H, Stolzel U. Does chloroquine therapy of porphyria cutanea tarda influence liver pathology? Int J Dermatol 2009; 48: 1250–3.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1250</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1250</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Combination of antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study</title></titleInfo><name type="personal"><namePart type="given">GC</namePart><namePart type="family">Ang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VP</namePart><namePart type="family">Werth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ang GC, Werth VP. Combination of antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005; 141: 855–9.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>141</number></detail><extent unit="pages"><start>855</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>141</number></detail><extent unit="pages"><start>855</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Successful treatment of necrobiosis lipoidica with antimalarial agents</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Durupt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Dalle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Debarbieux</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Balme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ronger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Thomas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Durupt F, Dalle S, Debarbieux S, Balme B, Ronger S, Thomas L. Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 2008; 144: 118–9.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>118</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>118</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Wallace</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Linker‐Israeli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Methger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VM</namePart><namePart type="family">Stecher</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wallace DJ, Linker‐Israeli M, Methger AL, Stecher VM. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993; 2(Suppl 1): S13–S15.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>S13</start><end>S15</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus.</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>S13</start><end>S15</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Canadian Consensus Conference on hydroxychloroquine</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 2000; 27: 2919–21.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>2919</start><end>21</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>2919</start><end>21</end></extent></part></relatedItem></relatedItem><identifier type="istex">1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A</identifier><identifier type="ark">ark:/67375/WNG-TF6GR5N0-G</identifier><identifier type="DOI">10.1111/j.1610-0387.2010.07490.x</identifier><identifier type="ArticleID">DDG7490</identifier><accessCondition type="use and reproduction" contentType="copyright">© The Author • Journal compilation © Blackwell Verlag GmbH, Berlin</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000024 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000024 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A
|texte= Use of antimalarials in dermatology
}}
| This area was generated with Dilib version V0.6.33. |  |